Evidence map›Paper›PMID 40862820›Full record

ArticleCurrent oncology (Toronto, Ont.)2025

Experiences of Advanced Non-Small Cell Lung Cancer Patients with Targeted Therapy Using Journey Mapping: A Qualitative Study.

Hailing Tu, Minghui Wang, Shengmei Yang, Jingfang Hong

Abstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hailing TuSchool of Nursing, Anhui Medical University, 81# Meishan Road, Hefei 230032, China.
Minghui WangSchool of Nursing, Anhui Medical University, 81# Meishan Road, Hefei 230032, China.
Shengmei YangSchool of Nursing, Anhui Medical University, 81# Meishan Road, Hefei 230032, China.
Jingfang HongSchool of Nursing, Anhui Medical University, 81# Meishan Road, Hefei 230032, China.ORCID 0000-0003-3226-2278

Funding

School of Nursing, Anhui Medical University, Graduate Seedling Cultivation Project Hlqm12025029School of Nursing, Anhui Medical University, Graduate Seedling Cultivation Project Hlqm12025031School of Nursing, Anhui Medical University, Graduate Seedling Cultivation Project Hlqm12025063the nationl natural science foundation of china 82272926
6 · The paper itself

Abstract

Targeted therapies against specific driver gene mutations have become the standard first-line treatment for most patients with advanced non-small cell lung cancer (NSCLC). While these therapies significantly prolong survival, the entire cancer treatment journey remains challenging and distressing. To better understand these experiences, this study employed a qualitative descriptive approach, conducting semi-structured interviews with 18 advanced NSCLC patients receiving targeted therapy, supplemented by patient journey logs. The resulting journey map delineated five stages: diagnosis, initial treatment, maintenance therapy, disease progression, and end-of-life. The analysis identified four key themes characterizing patient experiences at each stage. These findings enable healthcare professionals to identify risk situations and determine optimal timing for support interventions. Similarly, preparing patients for the processes they must undergo and the side effects of medical treatment helps reduce their uncertainty and anxiety, thereby improving their quality of life.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsMolecular Targeted TherapyAgedFemaleHumansMaleMiddle AgedQualitative ResearchQuality of Lifeadvanced non-small cell lung cancerpatient journey mappingprecision medicinequalitative interviewtreatment experience

Identifiers

PMID40862820
PMCPMC12384887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.